Calcium Phosphate Deposition With Normal Phosphate Concentration : – Role of Pyrophosphate –
スポンサーリンク
概要
- 論文の詳細を見る
Background: Calcium phosphate deposition (CPD) is the hallmark of vascular smooth muscle cell (VSMC) calcification. CPD is a thermodynamically-favored process under physiological conditions. Hydroxyapatite, the most common calcium phosphate in calcified arteries, is passively formed during VSMC calcification, independently on any direct cellular activity. Furthermore, in recent years it has been demonstrated there is an anti-calcifying effect by extracellular pyrophosphate, an endogenous inhibitor of CPD, both in vitro and in vivo, which directly blocks hydroxyapatite formation.Methods and Results: We have used the in vitro calcification model without cellular activity, by treating confluent rat aortic VSMC with paraformaldehyde. Fixed cells were incubated with the indicated media to obtain or inhibit calcification. The calcium content was determined colorimetrically. Calcification was observed after 3 weeks (21 days) using a physiological concentration of calcium (1.8mmol/L) and phosphate (1mmol/L). Calcium deposition was directly proportional to the amount of phosphate in the media, with a calcification rate of 3.5, 7.5, and 14.3μg·cm-2·day-1, using 1, 2, and 4mmol/L of phosphate, respectively. Under physiological conditions, pyrophosphate inhibits CPD with an IC50 of ≈200nmol/L.Conclusions: CPD occurs under a physiological concentration of calcium and phosphate, but this deposition is completely inhibited in the presence of a physiological concentration of pyrophosphate (3-5μmol/L). (Circ J 2011; 75: 2705-2710)
論文 | ランダム
- 新薬くろ〜ずあっぷ(89)コンサータ錠18mg,27mg
- 新薬くろ〜ずあっぷ(85)ケアロードLA錠60μg,べラサスLA錠60μg
- 10th International Congress of Therapeutic Drug Monitoring and Clinical Toxicologyに参加して
- 新薬くろ〜ずあっぷ(82)セララ錠25mg,50mg,100mg
- 滲出性中耳炎患者からのクラミジアの分離と同定